ENGLISH VERSION
China Health Technology Group Issues Clarification Announcement on Director’s Name
China Health Technology Group Holding Company Limited (Stock code: 1069) has issued a clarification announcement regarding the accurate English name of its executive Director, Chairman, and Chief Executive Officer. This announcement is particularly relevant for shareholders and investors, as it touches upon the integrity of company disclosures and the accuracy of information that may affect investor confidence.
Key Points of the Announcement
- Typographical Error Correction: The company disclosed that the English name of Ms. Bi Xue was incorrectly stated as “Bu Xue” in various company documents, including announcements, circulars, annual/interim reports, and other publications since August 14, 2023. The correct English name is “Bi Xue.” The Chinese name was always accurate.
- Timeline of Ms. Bi Xue’s Appointments:
- Appointed as Independent Non-Executive Director effective August 14, 2023
- Re-designated as Executive Director on April 1, 2025
- Appointed as Chief Executive Officer on December 1, 2025
- Appointed as Chairman of the Board on December 31, 2025
- Correction Applies to All Documents: All references to “Bu Xue” in documents since August 14, 2023 should be read as “Bi Xue.”
- No Other Changes: Aside from this name correction, all other information and particulars in the relevant documents remain unchanged.
- Board Composition: As of May 29, 2026, the Board includes Ms. Bi Xue and Ms. Wong Hoi Ying as executive Directors, with Mr. Chau Wing Nam, Ms. Liu Shuhua, and Mr. Li Liangjie serving as independent non-executive Directors.
Potential Shareholder and Price-Sensitive Implications
- Investor Confidence: The correction of a director’s name in official documents, while not affecting financial performance, is important for maintaining transparency and trust. Accurate disclosure is essential for regulatory compliance and investor relations.
- Corporate Governance: The series of appointments and re-designations involving Ms. Bi Xue signifies her increasing leadership role and influence within the company. Investors may interpret this as a sign of continuity and stable management, which can be positive for share value.
- Regulatory Compliance: The company’s prompt clarification and apology for the error demonstrates a commitment to robust governance practices. Any perceived lapses in disclosures could impact sentiment, but the proactive correction may help preserve investor confidence.
Conclusion
While the announcement is primarily administrative in nature, it is crucial for shareholders and investors to be aware of the correction to avoid confusion, especially when reviewing past or future company documents. The company’s leadership remains unchanged, and the clarification does not impact operational or financial performance.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions.
CANTONESE VERSION
中國健康科技集團發出董事姓名更正公告
中國健康科技集團控股有限公司（股份代號：1069）發出澄清公告，針對董事、董事會主席及行政總裁的英文姓名正確性作出更正。這公告對股東及投資者尤其重要，因為涉及公司資訊披露的誠信及準確性，有機會影響投資者信心。
公告重點
- 姓名拼寫錯誤更正： 公司披露，自2023年8月14日起，多份公司文件（包括公告、通函、年度/中期報告等）中，執行董事畢雪女士的英文名字誤寫為「Bu Xue」，正確應為「Bi Xue」。中文姓名一直正確。
- 畢雪女士任職時間線：
- 2023年8月14日獲委任為獨立非執行董事
- 2025年4月1日重任為執行董事
- 2025年12月1日獲任為行政總裁
- 2025年12月31日獲任為董事會主席
- 更正適用於所有文件： 自2023年8月14日以來所有提及「Bu Xue」的文件，均應視為「Bi Xue」。
- 其他資料無更動： 除姓名更正外，相關文件其他資料及內容維持不變。
- 董事會組成： 截至2026年5月29日，董事會包括畢雪女士及黃海瑩女士（執行董事），及周永楠、劉淑華、李良傑（獨立非執行董事）。
股東及價格敏感事項
- 投資者信心： 雖然姓名更正不影響財務表現，但對維持資訊透明及信任至關重要。準確披露是合規及投資者關係的核心。
- 公司管治： 畢雪女士連串職位任命及重任，反映其領導角色增強，投資者或視為管理層穩定，有利股價。
- 合規披露： 公司主動澄清及道歉，顯示管治嚴謹。若披露出現疏忽，或影響市場情緒，但及時修正有助維持投資者信心。
總結
公告主要屬行政性質，股東及投資者應留意此更正，避免因姓名混淆而產生誤解。公司管理層未有變動，此澄清不影響營運或財務狀況。
免責聲明
本文章僅供資訊參考，並不構成投資建議。投資者應自行進行盡職調查，並諮詢專業顧問後才作出任何投資決定。
